# Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/cost-effectiveness-analysis-of-rituximab-treatment-in-patients-in-germany-with/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Sonja Merkesdal,T. Kirchhoff,Diane Wolka,Gunter Ladinek,Adrian Kielhorn,Andrea Rubbert‐Roth |
| Citations | 36 |
| DOI | 10.1007/s10198-009-0205-y |
| Fields | Immunology and Microbiology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W1981122966 |
| PMID | 19967426 |
| Type | article |
| Year | 2009 |

## Paper authors

- [Adrian Kielhorn](https://scholariq.org/researchers/adrian-kielhorn/)

## Paper journal

- [The European Journal of Health Economics](https://scholariq.org/journals/the-european-journal-of-health-economics/)

## Paper primary topic

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)

## Paper topics

- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [Biosimilars and Bioanalytical Methods](https://scholariq.org/topics/biosimilars-and-bioanalytical-methods/)
- [Autoimmune and Inflammatory Disorders Research](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.